Ignite Creation Date:
2025-12-26 @ 10:32 AM
Ignite Modification Date:
2026-01-01 @ 4:55 AM
Study NCT ID:
NCT00390728
Status:
COMPLETED
Last Update Posted:
2010-08-31
First Post:
2006-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069036', 'term': 'Insulin Glargine'}], 'ancestors': [{'id': 'D049528', 'term': 'Insulin, Long-Acting'}, {'id': 'D061385', 'term': 'Insulins'}, {'id': 'D010187', 'term': 'Pancreatic Hormones'}, {'id': 'D036361', 'term': 'Peptide Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'count': 2346}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2002-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-08', 'completionDateStruct': {'date': '2003-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2010-08-30', 'studyFirstSubmitDate': '2006-10-18', 'studyFirstSubmitQcDate': '2006-10-19', 'lastUpdatePostDateStruct': {'date': '2010-08-31', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2006-10-20', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2003-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Main study: Frequency of severe hypoglycaemia'}, {'measure': 'Sub-study: The fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98) assessed at baseline, 3 months and study end point or upon withdrawal of the subject from the study.'}], 'secondaryOutcomes': [{'measure': 'Main study: HbA1c'}, {'measure': 'Incidence of nocturnal, symptomatic and asymptomatic hypoglycaemia'}, {'measure': 'Self monitored blood glucose'}, {'measure': 'Change in subject weight'}, {'measure': 'Changes in doses of insulin'}, {'measure': 'Changes in treatment satisfaction'}, {'measure': 'Safety assessment'}, {'measure': 'Quality of Life (QoL)using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)'}, {'measure': 'Sub-study:Quality of Life tools assessed at baseline, 3 months and at study end point or upon withdrawal of the subject'}, {'measure': 'Quality of Life - EQ-5D'}, {'measure': 'Hospital Anxiety and Depression Scale (HADS)'}, {'measure': 'Adverse events correlating with Quality of Life tools and hypoglycaemic events'}, {'measure': 'Medications for diabetes'}, {'measure': 'HbA1c'}, {'measure': 'Weight and height (BMI)'}, {'measure': 'Proportion of patients reaching HbA1c target as per participation with the Prescription Plan'}]}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 1']}, 'descriptionModule': {'briefSummary': 'Primary objective:\n\nAT.LANTUS main study\\*\n\n* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(\\*Target Number of patients for the main study:2346)\n\nHALT Sub-study\\*\\*\n\n* To test the hypothesis that titration regimens involving insulin glargine are associated with changes in the rate of symptomatic hypoglycaemic episodes together with changes in Fear of Hypoglycaemia as measured by the HFS-98 Questionnaire in Type I diabetes.(\\*\\*Target Number of patients for the Sub-study: 250)\n\nSecondary objectives:\n\nAT.LANTUS main study\n\nTo determine:\n\n* the incidence of symptomatic, asymptomatic and nocturnal hypoglycaemia with each treatment regimen\n* the difference in glycemic control as measured by HbA1c and fasting blood glucose with each treatment regimen\n* the difference in glycemic control as measured by HbA1c and fasting blood glucose between baseline and end of treatment\n* the safety on the use of insulin glargine in each treatment algorithm\n* the change in subject weight with each treatment regimen\n* the change in insulin doses with each treatment regimen\n* the change in Diabetes Treatment Satisfaction (Diabetes Treatment Satisfaction Questionnaire, sub-study only) with each treatment regimen\n\nHALT Sub-study (baseline to study end)\n\n* To estimate the relationship between change in HbA1c and incidence of hypoglycaemia\n* To examine the effect of insulin glargine on Quality of Life (EQ-5D) in relation to incidence of hypoglycaemia\n* To examine the effect of insulin glargine on the Hospital Anxiety and Depression Scale (HADS) in relation to the incidence of hypoglycaemia\n* To examine the use of the Prescription Plan versus standard management (no Prescription Plan)'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n* Subjects with type 1 diabetes mellitus who require a basal (long-acting) insulin for the control of hyperglycemia, with HbA1c values \\> 7.0% and \\< 12 %, and a body mass index (BMI) \\< 40 kg/m2.'}, 'identificationModule': {'nctId': 'NCT00390728', 'acronym': 'AT-LANTUS', 'briefTitle': 'Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Sanofi'}, 'officialTitle': 'A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ "HALT" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes', 'orgStudyIdInfo': {'id': 'HOE901_3505'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Insulin Glargine', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Patrick SINNASSAMY, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Sanofi'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}}}}